RTP Mobile Logo
Select Publications

Ahn IE et al. Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood 2019;133(22):2452-5. Abstract

Buhimschi AD et al. Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation. Biochemistry 2018;57(26):3564-75. Abstract

Burger JA et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2019;133(10):1011-9. Abstract

Fischer K et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380(23):2225-36. Abstract

Gauthier J et al. Efficacy and toxicity of CD19-specific chimeric antigen receptor T cells alone or in combination with ibrutinib for relapsed and/or refractory CLL. Proc Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR 2019;Abstract 10.

Ghia P et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IDR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). EHA 2019;Abstract LB2606.

Goede V et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: Final survival analysis of the CLL11 study. EHA 2018;Abstract S151.

Hallek M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131(25):2745-60. Abstract

Jain N et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med 2019;380(22):2095-103. Abstract

Janus A, Robak T. Moxetumomab pasudotox for the treatment of hairy cell leukemia. Expert Opin Biol Ther 2019;19(6):501-8. Abstract

Kater AP et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: Post-treatment follow-up of the MURANO phase III study. J Clin Oncol 2019;37(4):269-77. Abstract

Kreitman RJ et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia 2018;32(8):1768-77. Abstract

Moreno C et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20(1):43-56. Abstract

Roeker LE et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clin Cancer Res 2019;25(14):4264-70. Abstract

Shanafelt TD et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381(5):432-43. Abstract

Shanafelt TD et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs standard f ludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): A trial of the ECOG-ACRIN Cancer Research Group (E1912). Proc ASH 2018;Abstract LBA-4.

Siddiqi T et al. TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lympho­cytic lymphoma (CLL/SLL). ASCO 2019;Abstract 7501.

Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 2019;133(12):1298-307. Abstract

Stilgenbauer S et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: Results from the full population of a phase II pivotal trial. J Clin Oncol 2018;36(19):1973-80. Abstract

Woyach JA et al. Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/ refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up. ASCO 2019;Abstract 7500.

Woyach JA et al. Ibrutinib alone or in combination with rituximab produces superior progres­sion free survival (PFS) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Proc ASH 2018;Abstract 6.

Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379(26):2517-28. Abstract